Trial Profile
Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of MP03-36 [azelastine] and MP03-33 [azelastine] in Patients With Perennial Allergic Rhinitis.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Jun 2011
Price :
$35
*
At a glance
- Drugs Azelastine (Primary)
- Indications Perennial allergic rhinitis
- Focus Therapeutic Use
- Sponsors Meda Pharmaceuticals
- 02 Aug 2008 New trial record.